Physicians' Academy for Cardiovascular Education

VBWG: US Chapter meeting at ACC

Mar. 4, 2013


 
 
Held on March 28th at the Grand Hyatt Washington, DC prior to ACC 2014

Webcasts with faculty will be posted soon

Agenda

1:30—2:00 Registration Independence Ballroom Foyer

2:00—2:05 Welcome and Introductions
Carl J. Pepine, MD, MACC, University of Florida


Keynote Address

2:05—2:25  Renal Denervation for Resistant Hypertension: Did SYMPLICITY 3 Scorch the Future?
Thomas F. Luscher, MD, FACC, University Hospital Zurich,  Zurich, Switzerland


Session I – Novel Methods to Modify Risk

2:25—2:40 New Approaches to Modifying Risk by Improved Glycemic Management: SGLT2 Inhibition, Incretin Therapy and the Future
Deepak L. Bhatt, MD, MPH, FACC,  Harvard Medical School, Boston, MA

2:40—2:55 Future Pharmacological Options for Heart Failure
Christopher O’Connor, MD, FACC, Duke University Medical Center, Durham, NC

2:55—3:10 PCSK9 Inhibitors and the Unmet Need for LDL Cholesterol Reduction
Evan A. Stein, MD, PhD, FCAP, University of Cincinnati, Cincinnati, OH


Session II – Stroke Prevention

3:20—3:35 Is Left Atrial Appendage Occlusion Really an Alternative to Lifelong Anticoagulation?
David R. Holmes Jr., MD, MACC, Mayo Clinic, Rochester, MN

3:35—3:50 Translating Clinical Trial Results of Novel Anticoagulants for Stroke Prevention into Clinical Practice
Michael Ezekowitz, MD, PhD, FACC, Thomas Jefferson Medical College, Philadelphia, PA

3:50—4:00 Discussion


Session III – Looking Over the Horizon in 2014

4:00—4:15 Key Lessons Learned From Cell Therapy Clinical Trials: Advances in Delivery Systems and Applications
Andreas M. Zeiher, MD, Goethe University, Frankfurt, Germany

4:15—4:30 A Novel Approach to Preventing Aortic Stenosis
Jean-Claude Tardif, MD, FACC, Montreal Heart Institute, Montreal, Quebec

4:30—4:45 Serelaxin: “Breakthrough Therapy” or “Also Ran”
John R. Teerlink, MD, FACC, UCSF School of Medicine, San Francisco, CA

4:45—4:55 Discussion